rossgivens

rossgivens

Exact Sciences is a biotech stock showing high relative strength. Following a 50% jump in January, the stock is tightening with pullbacks getting shallower from left to right. This is a sign of seller digestion which we often see before a new breakout to the upside. EXAS is also finding support at key moving averages which appear to be holding up the stock. I...

rossgivens

ONON is the maker of the popular OnCloud running shoes. The company has experienced tremendous growth over the last few years. I even see it here. They are on the feet on every soccer mom in town. Last month’s earnings report blew away expectations and shares advanced almost 50% in a week. Since then, pullbacks have been minimal. This is a recent IPO, and it...

rossgivens

HIMS is an exciting new company taking the awkward discomfort out of sensitive medical issues for men and women. They have two sites – Hims and Hers. The sites are catered to each gender and offer hair loss medications, prescription skin cream, anxiety drugs, and sexual dysfunction treatments via quick, online doctor visits. The company then ships the drugs or...

rossgivens

Life Time owns and operates a chain of “athletic country clubs.” They are basically high-end gyms offering everything from free weights and elliptical machines to steam saunas and smoothie bars. The company went public in late 2021, right before the bear market began. But the stock is now soaring… I have circled the signs of accumulation in the volume...

rossgivens

TOST went public in late 2021 - just in time to get slaughtered in last year's bear market. But the stock is now turning around. I like the late-2021 and 2022 IPO bucket since a lot of these names have not had a chance to shine in a healthy market. Many are trading for a fraction of their IPO price and beginning to shine. TOST is one of them. After nearly...

rossgivens

CPRX is the #1 stock in the biotech group by almost every metric. The table on the chart shows its ranking out of all 795 biotech stocks by 3 metrics from IBD's MarketSmith. Sales and earnings are surging and the rate at which both are growing has increased in each of the last 4 quarters. The stock made a false breakout on December 14 when the market gapped up...

rossgivens

Agilysys ($AGYS) is showing tremendous strength here. After news the company inked a property management deal with Marriott last month, shares surged 33% in 2 days with minimal retracement. AGYS is now forming a small consolidation base in the $76-$80 range and holding its 10-day moving average (yellow line). I am taking a small pilot position here with a stop...

rossgivens

Haliburton is setting up in a volatility contraction pattern trying to break out higher. There is supply at the $40 level, so I want to buy on a pullback off that level to create a profit cushion in case it fails there again. There is also a longer-term cup with handle pattern here with $40 being the top of the handle. Volume is drying up in the base which...

rossgivens

RBC is seeing incredible growth. I've overlaid the last 4 quarters of sales and earnings growth from MarketSmith on the chart. Any company that can double their sales every quarter for a year has explosive upside. The numbers of institutional funds who own the stock is steadily growing, and it is owned by some of the best-performing mutual funds including T.Rowe...

rossgivens

Abcellera Biologics is a biotech stock setting up in a textbook cup with handle pattern. The stock has growing institutional sponsorship as shown in the chart from MarketSmith on the chart. It also has a relative strength ranking of 97/100. Shares formed a cup with a 37% depth and have since drifted back slightly to form a defined handle. I will consider buying...

rossgivens

NextEra is a clean energy company with interests in wind and solar projects across North America. The stock showed a lot of strength for several months, but has now become a broken leader. NEP broke down below the previous breakout level (white dotted line on chart) and below its 200-day moving average. The short-term rally in the stock now gives a low-risk...

rossgivens

AMPS is coming out of a textbook cup with handle pattern, triggering a buy here. AMPS is somewhat of an under-the-radar solar stock. Unlike most solar companies which make panels, chips, or mounting systems for customer-owned solar energy systems, Altus is an electric utility company whose power comes exclusively from solar generation. I actually prefer the...

rossgivens

The S&P 500 posted a 92% up day on Friday the 4th day with at least 90% advancing volume since the June low. Everyone loves to be a bear, but I continue to believe the lows are in. Inflation has peaked and the Fed is being aggressive to ensure that remains the case. Everything else is already priced in. We also held the 3900 level which was crucial. This is...

rossgivens

Kroger reported earnings that beat out Wall Street’s estimates on Friday. People continued to prioritize at-home food consumption amid high inflation. This trend resulted in Kroger raising its full-year outlook, and we will likely see analysts raising their targets for the stock as well. Shares jumped 7.4% on the news, making it one of the top performers in the...

rossgivens

Dicks Sporting Goods (DKS) is breaking out from a textbook cup with handle pattern. After nearly doubling in price between May and August, the stock stalled and formed a small pivot at the $115 resistance level. Relative strength has been climbing for several months - a sign that Dicks has been leading the surge higher and outperforming the rest of the...

rossgivens

CSIQ is a market leader in today’s #1 sector - solar energy. Shares soared over 60% between July and August as solar stocks came front and center as a leading theme in the market recovery. The 200-day moving average has begun sloping upward, putting CSIQ at the beginning of a new Stage 2 uptrend (see my previous post on the 4 Stages of the Stock Cycle). The pink...

rossgivens

Catalyst Pharma (CPRX) is an absolute monster. Not only is the company posting huge sales and earnings growth in a sector that rarely has either, the stock has more than doubled over the last few months. There are 801 stocks in the biotech group tracked by Investors Business Daily, and CPRX ranks at the very top (see image in chart). After such a large advance...

rossgivens

NBIX is in the biotech sector which I have been highlighting for several months as one of the strongest areas in the market. After emerging from a textbook breakout pattern in early August, shares have consolidated in a tight handle formation. If you look at the relative strength line at the top of the chart, you will notice three pink dots over the last several...